Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOPE ATRT01 umbrella trial in children with ATRT
2022-501456-28-00Phase 3Authorised
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Jul 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of thiotepa, carboplatin, cyclophosphamide, actinomycin D, doxorubicin and 4 more in Atypical teratoid rhabdoid tumor (ATRT) (4 arms), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Overall survival. Planned start Jul 2020; status: authorised.
02
Drugs
thiotepacarboplatincyclophosphamideactinomycin Ddoxorubicin
03
Conditions
Atypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on 2022-501456-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501456-28-00.